ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

September 28, 2012

Sen. Brown Introduces Bill on Clinical Trials Coverage

April 3, 2009

AACR to honor eight scientists with lecture awards.

February 13, 2004

Biotherapeutics Reports LAK/IL-2 Toxicity Reduced With Constant Infusion Of IL-2

April 17, 1987

NCI Director John Niederhuber Favors Hands-On Management, Revives Institute’s Former Organizational Structure, Abandons Senior Management Team to Work Closely With Deputies and Division Directors.

September 22, 2006

In Brief: Bertino Moves To MSK As Head Of Chemotherapy Research; Rosemary Clive Laves ACOS For Elm

January 2, 1987